Modulation of mTORC1 and IL-6 following mirror therapy and pregabalin in complex regional pain syndrome type 1.

Source: Pain Manag 2023 Jan 06; . doi: 10.2217/pmt-2022-0020Authors: Saxena A K, Malik A, Singh A, Chilkoti GT, Bhardwaj N, Bajaj M, Banerjee B D, Banerjee B D

The study was designed to evaluate the modulation of mTOR complex 1 (mTORC1) and IL-6 genes following the use of mirror therapy (MT) and pregabalin in complex regional pain syndrome type-1 patients. Two groups of 20 patients: MT group received MT and pregabalin, control therapy group received pregabalin. Neuropathic pain symptom inventory (NPSI), numeric rating scale – pain, modified motor activity log, SF-12 questionnaire for quality of life and IL-6 and mTORC1 expression were evaluated. Group MT demonstrated a statistically significant improvement in NPSI burning, NPSI allodynia and numeric rating scale pain scores, modified motor activity log and SF-12 scores. Significant downregulation of mTORC1 and IL-6 observed in both. MT is a significant adjunct to pregabalin in improving motor function, quality of life and alleviating pain in complex regional pain syndrome type 1. : CTRI/2019/01/017272 (ClinicalTrials.gov).

Pubmed ID: http://www.ncbi.nlm.nih.gov/pubmed/36606500?dopt=Abstract